Inhalopédia | Inhalers

Class
- Long-acting muscarinic antagonist (LAMA)
  Long-acting beta-2 agonist (LABA)
Active ingredient
- Umeclidinium (as bromide)
- Vilanterol (as trifenatate)
Device
- Ellipta®
Inhalers techniques and maintenance
Age
- 18 +
Typical use
- Asthma (off-label)
  in addition to an ICS, when uncontrolled on high dose ICS + LABA
Asthma management principles
- COPD
  uncontrolled on 1 bronchodilator (LAMA or LABA)
COPD management principles
Marketed strength
- 62.5/25 mcg
Number of doses
- 30 doses
Dose indicator
- Yes | Numerical
Usual adult dosage
- 1 inh QD
Usual pediatric dosage
- -
Required inspiratory flow
- > 30 - 60 L/min
  Medium-low internal resistance (R2)
Inspiratory flows
Public coverage
- MN – NIHB | Open/Regular Benefit
  All provinces except MN – NIHB | Restricted Benefit with criteria
Provincial coverage criteria
Advantages
- Easy handling
- Precise dose counter
Disadvantages
- Taste that can be unpleasant
- Lip sealing difficult for some older patients
Side effects

Product monograph

Download

Anoro®